Ambrx Biopharma Cayman, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040568 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $235.1M $110.9M
YoY Change 112.0% -33.68%
Cash & Equivalents $228.3M $65.64M
Short-Term Investments $6.824M $45.25M
Other Short-Term Assets $981.0K $7.876M
YoY Change -87.54% 59.43%
Inventory
Prepaid Expenses
Receivables $81.00K $1.466M
Other Receivables $2.231M $771.0K
Total Short-Term Assets $241.4M $121.0M
YoY Change 99.5% -30.07%
LONG-TERM ASSETS
Property, Plant & Equipment $3.195M $15.01M
YoY Change -78.71% 407.47%
Goodwill
YoY Change
Intangibles $24.94M
YoY Change
Long-Term Investments $0.00 $18.83M
YoY Change -100.0%
Other Assets $357.0K $466.0K
YoY Change -23.39% 15.92%
Total Long-Term Assets $38.53M $59.86M
YoY Change -35.64% 47.1%
TOTAL ASSETS
Total Short-Term Assets $241.4M $121.0M
Total Long-Term Assets $38.53M $59.86M
Total Assets $279.9M $180.9M
YoY Change 54.78% -15.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.362M $5.696M
YoY Change 11.69% 51.17%
Accrued Expenses $9.556M $16.91M
YoY Change -43.47% 79.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.18M $25.74M
YoY Change -29.37% 47.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.51M $12.36M
YoY Change -15.01% 382.06%
Total Long-Term Liabilities $10.51M $12.36M
YoY Change -15.01% 382.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.18M $25.74M
Total Long-Term Liabilities $10.51M $12.36M
Total Liabilities $29.56M $38.98M
YoY Change -24.15% 86.25%
SHAREHOLDERS EQUITY
Retained Earnings -$324.8M
YoY Change
Common Stock $43.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $250.4M $141.9M
YoY Change
Total Liabilities & Shareholders Equity $279.9M $180.9M
YoY Change 54.78% -15.37%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001836056
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Accounts Payable Related And Nonrelated Party Status Extensible Enumeration
AccountsPayableRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableCurrent
CY2022Q4 us-gaap Accounts Payable Related And Nonrelated Party Status Extensible Enumeration
AccountsPayableRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40505
dei Entity Registrant Name
EntityRegistrantName
Ambrx Biopharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Address Address Line1
EntityAddressAddressLine1
10975 North Torrey Pines Road
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Country
EntityAddressCountry
US
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
875-2400
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
434070056
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
228265000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
55610000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
665000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
831000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
6824000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28873000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
81000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
376000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4893000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
241413000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
90583000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
16793000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3195000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3044000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10044000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10968000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24935000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25250000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
357000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
339000
CY2023Q2 us-gaap Assets
Assets
279944000
CY2022Q4 us-gaap Assets
Assets
146977000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6362000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3205000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9556000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11314000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1854000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1734000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
407000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
407000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18179000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16660000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9163000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10245000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
880000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
880000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1342000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1342000
CY2023Q2 us-gaap Liabilities
Liabilities
29564000
CY2022Q4 us-gaap Liabilities
Liabilities
29127000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
432227488
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
432227488
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
270455232
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
270455232
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
43000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
576046000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
410753000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-953000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1302000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324756000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291628000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
250380000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117850000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279944000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146977000
CY2023Q2 us-gaap Revenues
Revenues
1123000
CY2022Q2 us-gaap Revenues
Revenues
1299000
us-gaap Revenues
Revenues
1147000
us-gaap Revenues
Revenues
2912000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14393000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18062000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24143000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32766000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5900000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4823000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12206000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9393000
CY2023Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
7195000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
9660000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20293000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
30080000
us-gaap Operating Expenses
OperatingExpenses
36349000
us-gaap Operating Expenses
OperatingExpenses
51819000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19170000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28781000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35202000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48907000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1428000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
223000
us-gaap Investment Income Net
InvestmentIncomeNet
1979000
us-gaap Investment Income Net
InvestmentIncomeNet
223000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
211000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-11000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
401000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-965000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-144000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-124000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1649000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
68000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-866000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17521000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28713000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32750000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49773000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
305000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
129000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
378000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1716000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-17826000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28842000
us-gaap Profit Loss
ProfitLoss
-33128000
us-gaap Profit Loss
ProfitLoss
-51489000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
391283214
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
391283214
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
270160166
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
270160166
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353337365
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353337365
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
270142269
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
270142269
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-17826000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28842000
us-gaap Profit Loss
ProfitLoss
-33128000
us-gaap Profit Loss
ProfitLoss
-51489000
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-13000
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-217000
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-39000
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-217000
CY2023Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-36000
CY2022Q2 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-388000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-217000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
349000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-217000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17803000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29059000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-32779000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-51706000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
182592000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2095000
CY2023Q2 amam Issuance Of Ordinary Shares For Cash Through Registered Direct Offering With A Related Party Net Of Issuance Costs Value
IssuanceOfOrdinarySharesForCashThroughRegisteredDirectOfferingWithARelatedPartyNetOfIssuanceCostsValue
74663000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8042000
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
791000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
23000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17826000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
250380000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117850000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4033000
amam Issuance Of Ordinary Shares For Cash Through At The Market Offering Net Of Issuance Costs
IssuanceOfOrdinarySharesForCashThroughAtTheMarketOfferingNetOfIssuanceCosts
77780000
amam Issuance Of Ordinary Shares For Cash Through Registered Direct Offering With A Related Party Net Of Issuance Costs Value
IssuanceOfOrdinarySharesForCashThroughRegisteredDirectOfferingWithARelatedPartyNetOfIssuanceCostsValue
74663000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8042000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
791000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
349000
us-gaap Net Income Loss
NetIncomeLoss
-33128000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
250380000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
168977000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1879000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
95000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-217000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28842000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
141892000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
189967000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3529000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
102000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-217000
us-gaap Net Income Loss
NetIncomeLoss
-51489000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
141892000
us-gaap Profit Loss
ProfitLoss
-33128000
us-gaap Profit Loss
ProfitLoss
-51489000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
9660000
us-gaap Share Based Compensation
ShareBasedCompensation
4824000
us-gaap Share Based Compensation
ShareBasedCompensation
3529000
amam Non Cash Lease Expense
NonCashLeaseExpense
1366000
amam Non Cash Lease Expense
NonCashLeaseExpense
1123000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
418000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
365000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
315000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
737000
amam Amortization Of Investment Securities Net
AmortizationOfInvestmentSecuritiesNet
-326000
amam Amortization Of Investment Securities Net
AmortizationOfInvestmentSecuritiesNet
-57000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-295000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
227000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
705000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
877000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3154000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
861000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-926000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1621000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1402000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1404000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-803000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26117000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40195000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40645000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
63301000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
54263000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
25900000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
783000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
903000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38735000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64204000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
166000000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
166000000
amam Payments Of Directors And Officers Insurance Premium Financing Agreement
PaymentsOfDirectorsAndOfficersInsurancePremiumFinancingAgreement
932000
amam Payments Of Directors And Officers Insurance Premium Financing Agreement
PaymentsOfDirectorsAndOfficersInsurancePremiumFinancingAgreement
0
amam Proceeds From Issuance Of Commonstock For Cash Net Of Issuance Costs
ProceedsFromIssuanceOfCommonstockForCashNetOfIssuanceCosts
77780000
amam Proceeds From Issuance Of Commonstock For Cash Net Of Issuance Costs
ProceedsFromIssuanceOfCommonstockForCashNetOfIssuanceCosts
0
amam Proceeds From Issuance Of Ordinary Shares For Cash Through Direct Offering With Related Party Net Of Issuance Costs
ProceedsFromIssuanceOfOrdinarySharesForCashThroughDirectOfferingWithRelatedPartyNetOfIssuanceCosts
74981000
amam Proceeds From Issuance Of Ordinary Shares For Cash Through Direct Offering With Related Party Net Of Issuance Costs
ProceedsFromIssuanceOfOrdinarySharesForCashThroughDirectOfferingWithRelatedPartyNetOfIssuanceCosts
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8042000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
102000
amam Payments Of Common Stock Issuance Costs
PaymentsOfCommonStockIssuanceCosts
0
amam Payments Of Common Stock Issuance Costs
PaymentsOfCommonStockIssuanceCosts
136000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159871000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-34000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
172489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104433000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56441000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
170906000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
228930000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66473000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
963000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
amam Propertyandequipmentcostsinaccountspayableandaccruedliabilities
Propertyandequipmentcostsinaccountspayableandaccruedliabilities
277000
amam Propertyandequipmentcostsinaccountspayableandaccruedliabilities
Propertyandequipmentcostsinaccountspayableandaccruedliabilities
0
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
318000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0
amam Unsettled Trade Of Marketable Debt Securitiesavailable For Sale
UnsettledTradeOfMarketableDebtSecuritiesavailableForSale
0
amam Unsettled Trade Of Marketable Debt Securitiesavailable For Sale
UnsettledTradeOfMarketableDebtSecuritiesavailableForSale
989000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to the valuation of share-based awards and MDS, the discount rate used in estimating the present value of the right-of-use (ROU) assets and lease liabilities, the useful lives of property and equipment and intangible assets, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, deferred income taxes and related valuation allowances, and the assessment of the Company’s ability to fund its operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to recent disruptions in access to bank deposits and lending commitments associated with bank failures, the COVID-19 pandemic and macroeconomic and geopolitical conditions, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2023. While there was no material impact to the Company’s condensed consolidated financial statements as of and for the three and six months ended June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, these estimates may change, as new events occur and additional information is obtained, which could materially impact the Company’s condensed consolidated financial statements in future reporting periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, MDS, and accounts receivable which are generally not collateralized. Deposits in the Company’s checking and money market accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. In addition, the Company maintains cash and cash equivalents in foreign bank accounts, which are not federally insured.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company attempts to minimize credit risk associated with its cash and cash equivalents by periodically evaluating the credit quality of its primary financial institutions. The Company’s investment portfolio is maintained in accordance with its investment policy, which is designed to preserve capital, safeguard funds and limit exposure to risk. While the Company maintains cash deposits in Federal Deposit Insurance Corporation insured financial institutions in excess of federally insured limits, it does not believe that it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on such accounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the three months ended June 30, 2023 and 2022, revenues from the Company’s top customer represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of total revenues, respectively. During the six months ended June 30, 2023, revenues from the Company’s top customer represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of total revenues. During the six months ended June 30, 2022, revenues from the Company’s top two customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of total revenues, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of June 30, 2023, billed accounts receivable for the top two customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of total billed receivables, respectively. As of June 30, 2022, billed accounts receivable for the top two customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of total billed receivables, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228265000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65642000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
665000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
831000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
228930000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66473000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2023Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49392442
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39829831
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49392442
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39829831
CY2023Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2231000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1506000
CY2023Q2 amam Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
1277000
CY2022Q4 amam Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
1476000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1089000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1424000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
981000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
487000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4893000
CY2023Q2 amam Prepaid Research And Development Costs Due To Related Party
PrepaidResearchAndDevelopmentCostsDueToRelatedParty
76000
CY2022Q4 amam Prepaid Research And Development Costs Due To Related Party
PrepaidResearchAndDevelopmentCostsDueToRelatedParty
14000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9216000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8661000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6021000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5617000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3195000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3044000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
400000
CY2023Q2 amam Accrued Research And Development Costs To Related Party Current
AccruedResearchAndDevelopmentCostsToRelatedPartyCurrent
3063000
CY2022Q4 amam Accrued Research And Development Costs To Related Party Current
AccruedResearchAndDevelopmentCostsToRelatedPartyCurrent
4069000
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2924000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3494000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2189000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1703000
CY2023Q2 amam Accrued Directors And Officers Insurance Premium Financing Obligation Current
AccruedDirectorsAndOfficersInsurancePremiumFinancingObligationCurrent
0
CY2022Q4 amam Accrued Directors And Officers Insurance Premium Financing Obligation Current
AccruedDirectorsAndOfficersInsurancePremiumFinancingObligationCurrent
926000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1380000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1122000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9556000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11314000
CY2023Q2 amam Accrued Research And Development Costs Related Party
AccruedResearchAndDevelopmentCostsRelatedParty
39000
CY2022Q4 amam Accrued Research And Development Costs Related Party
AccruedResearchAndDevelopmentCostsRelatedParty
99000
CY2023Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
28350000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-3415000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24935000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
45270000
CY2022 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
9660000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-10360000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25250000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2022 amam Weighted Average Remaining Contractual Life On Debt Securities Available For Sale
WeightedAverageRemainingContractualLifeOnDebtSecuritiesAvailableForSale
P0Y8M12D
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46175000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
512000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
45666000
CY2023Q2 amam Interest Receivable From Marketable Debt Securities Current
InterestReceivableFromMarketableDebtSecuritiesCurrent
100000
CY2022Q4 amam Interest Receivable From Marketable Debt Securities Current
InterestReceivableFromMarketableDebtSecuritiesCurrent
200000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6824000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
163000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
673000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
38185000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
512000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
3
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
217000
CY2022Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
147000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
569000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
147000
CY2023Q2 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1247000
CY2022Q2 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
76000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1798000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
76000
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-36000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-388000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1428000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
223000
us-gaap Investment Income Net
InvestmentIncomeNet
1979000
us-gaap Investment Income Net
InvestmentIncomeNet
223000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1083000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
957000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2337000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1915000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
206000
us-gaap Operating Lease Payments
OperatingLeasePayments
1404000
us-gaap Operating Lease Payments
OperatingLeasePayments
803000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0763
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0763
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0763
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0763
CY2023Q2 amam Commission On Sale Of Common Stock
CommissionOnSaleOfCommonStock
300000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1123000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1299000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1147000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2912000
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
1700000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
1700000
CY2023Q2 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
81000
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss Current
ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
376000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1749000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1749000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2886000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1879000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4824000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3529000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2886000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1879000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4824000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3529000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
39116174
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.11
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1088000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
16663805
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7558033
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2919504
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.32
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
45302442
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.71
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
74829000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
17698142
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.72
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
29001000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y4M24D
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6600000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
0
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2023Q2 amam Prepaid Research And Development Expenses Related Parties Current And Noncurrent
PrepaidResearchAndDevelopmentExpensesRelatedPartiesCurrentAndNoncurrent
76000
CY2022Q4 amam Prepaid Research And Development Expenses Related Parties Current And Noncurrent
PrepaidResearchAndDevelopmentExpensesRelatedPartiesCurrentAndNoncurrent
14000
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
58000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
352000
CY2023Q2 amam Accrued Liabilities Related Parties Current And Noncurrent
AccruedLiabilitiesRelatedPartiesCurrentAndNoncurrent
39000
CY2022Q4 amam Accrued Liabilities Related Parties Current And Noncurrent
AccruedLiabilitiesRelatedPartiesCurrentAndNoncurrent
99000
CY2023Q2 amam Payments To Related Party
PaymentsToRelatedParty
158000
CY2022Q2 amam Payments To Related Party
PaymentsToRelatedParty
14000
amam Payments To Related Party
PaymentsToRelatedParty
510000
amam Payments To Related Party
PaymentsToRelatedParty
269000
CY2023Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
10000
CY2022Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
289000
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
94000
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
469000

Files In Submission

Name View Source Status
0000950170-23-040568-index-headers.html Edgar Link pending
0000950170-23-040568-index.html Edgar Link pending
0000950170-23-040568.txt Edgar Link pending
0000950170-23-040568-xbrl.zip Edgar Link pending
amam-20230630.htm Edgar Link pending
amam-20230630.xsd Edgar Link pending
amam-ex31_1.htm Edgar Link pending
amam-ex31_2.htm Edgar Link pending
amam-ex32_1.htm Edgar Link pending
amam-ex32_2.htm Edgar Link pending
amam-ex3_2.htm Edgar Link pending
amam-ex4_3.htm Edgar Link pending
amam-ex4_4.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img46787537_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
amam-20230630_lab.xml Edgar Link unprocessable
amam-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amam-20230630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
amam-20230630_cal.xml Edgar Link unprocessable
amam-20230630_def.xml Edgar Link unprocessable